Paroxysmal or chronic atrial fibrillation (AF) develops in about 20- 25% of adult patients with hypertrophic cardiomyopathy (HCM) and represents an important complication in the clinical course of the disease, with adverse long-term consequences on functional status and outcome. Therefore, aggressive therapeutic strategies are indicated to restore and maintain sinus rhythm (SR) in patients with HCM. Nevertheless, pharmacologic prevention of AF recurrence is challenging because of the limited long-term efficacy and potentially hazardous side effects of available treatment options. Currently radiofrequency catheter ablation (RFCA) of AF is successfully used in clinical practice. However, comparison of the efficacy and safety of these two therapeutic options has not been done up till now in randomized manner in this group of patients. Thus, the aim of the present study is to compare the efficacy and safety of RFCA vs. antiarrhythmic drug therapy in patients with HCM and AF.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
90
RF catheter ablation
One of AA drugs (preferably Amiodarone) and cardioversion in cases of chronic AF
Institute of Cardiology
Warsaw, Poland
Efficacy: Freedom from atrial fibrillation and atrial flutter (>1 min) on or off antiarrhythmic medications.
Time frame: 1 year
Changes in total symptomatic and asymptomatic AF burden.
Time frame: 1 year
Incidence of complications.
Time frame: 1 year
Changes in left atrial diameter and left ventricular function.
Time frame: 1 year
Changes in level of Nt-pro-BNP.
Time frame: 1 year
Changes in symptom severity and quality of life.
Time frame: 1 year
Changes in exercise capacity assessed by cardiopulmonary exercise testing.
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.